Pharmaceutical pioneer Trek Therapeutics, PBC, (Trek) a privately-held, clinical-stage, public-benefit, for-profit corporation that is developing affordable and accessible proprietary treatments for infectious diseases, was featured in a Milano Finanza-Dow Jones article reporting on the recently announced partnership between Trek and Ambrosus to apply integrated sensors coupled with blockchain-based technology to pharmaceutical drug manufacturing in Trek’s clinical development program. The Italian-language article, entitled “Finanza: Ambrosus sigla accordo con Trek T. per protocollo blockchain” (translation: “Finance: Ambrosus signs agreement with Trek T. for blockchain protocol”) was published on the Milano Finanza website on August 21.

Combining high-tech sensors, blockchain, and powered by smart contracts, Ambrosus is building the world’s first publicly-verifiable, community-driven ecosystem to ensure the quality, safety, and origins of essential products, such as medicine, food, and commodities. As part of the collaboration, Ambrosus will conduct pilot projects with Trek to monitor the quality, safety, and integrity of all stages of the pharmaceutical manufacturing process.

Trek Co-founder and CEO Dr. Ann Kwong said, “We are extremely gratified to be featured in two Milano Finanza-Dow Jones articles within the past month, the first being an introduction to Trek and its mission to provide cost-effective, affordable, and accessible drugs to treat patients that suffer from infectious diseases, starting with hepatitis C virus (HCV) infection, and our current fundraising efforts.”

Trek Therapeutics, PBC is a privately-held, public-benefit corporation developing treatments for serious infections. Its mission is to provide cost-effective, affordable, and accessible medicines to treat patients that suffer from infectious diseases and commercialize them for global populations. Since the company’s founding in 2014, Trek has raised US$10M in Series A funding. Trek’s management team and board of directors are comprised of seasoned drug- development executives from Vertex, Schering Plough/Merck, Pharmasset/Gilead, Bristol-Myers Squibb, Roche, Celgene Global Health, Idenix, and Genzyme.

About Trek Therapeutics
Trek Therapeutics, PBC is a private, clinical stage public benefit corporation developing treatments for serious infections. Its mission is to profitably develop affordable and accessible medicines to treat infectious diseases and to commercialize them for global populations starting with hepatitis C virus (HCV) infection. Its commercial strategy is to price their treatment regimen low enough to include the majority of patients infected with HCV who cannot afford the expensive treatments available today. Trek is currently raising Series B financing to support the completion of its Phase 2a program and initiate its Phase 2b studies. Trek is examining the possibility of a listing on the Euronext Growth and other markets. For further information, please visit

About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President have more than 20 years’ experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations—all of whom are also exclusively invited to match MFG’s highly selective criteria.